Initially, we considered both CXCR4 and CXCR7 to study the impact of these two chemokine receptors to understand therapy resistance in cancer as they share CXCL12 as a common ligand, and are shown to be overexpressed in different solid tumors14,17. This evidence concerns the gene CXCL12 and cancer.